The purpose of this study is to prospectively study the efficacy of low dose ketamine
infusions in treating patients who are admitted to the hospital with a sickle cell pain
crisis. Participants will be prospectively randomized in unblinded fashion in the first 12 to
24 hours of an inpatient admission for sickle cell pain crisis to receive pain management
without ketamine infusion (Group A) versus pain management that includes low-dose ketamine
infusion starting at 0.2mg/kg/h (Group B). The effect of this intervention on various pain
management and healthcare utilization outcome measures will be recorded and analyzed to
determine whether or not there is a measurable benefit of using ketamine infusions in this
patient population.